Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Poziotinib
Sponsor: Spectrum Pharmaceuticals, Inc